You are here: Industry Insights > ozanimod

News List

UK NICE rejects NHS use of ozanimod for MS treatment pharmaceutical-technology
May 17, 2021
The UK National Institute for Health and Care Excellence (NICE) has decided not to recommend ozanimod for the treatment of relapsing multiple sclerosis (MS) patients on National Health Service (NHS) in England and Wales.
Once daily multiple sclerosis treatment approved for use in Scotland europeanpharmaceuticalreview
February 10, 2021
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
The FDA drug decisions to watch in the first quarter of 2020 fiercepharma
January 06, 2020
It's a new year, which means it's a new opportunity for drugmakers hoping to pass FDA muster for new therapies––some of which could be sniffing after blockbuster sales.
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis drugs
June 11, 2019
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis.
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis drugs
April 11, 2019
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis.
Celgene resubmits MS drug, ozanimod, to FDA pharmatimes
March 28, 2019
After a failed attempt in 2017, Celgene has decided to refile its relapsing remitting multiple sclerosis (RRMS) drug, ozanimod, with the US Food and Drug Administration (FDA).
Celgene files for EU approval of ozanimod in relapsing-remitting MS, with US re-submission on track firstwordpharma
March 12, 2019
Celgene on Monday announced the filing of a marketing application in Europe seeking approval of the oral, sphingosine 1-phosphate receptor modulator ozanimod for the treatment of relapsing-remitting multiple sclerosis.
After FDA rebuff, Celgene on track to refile ozanimod—in 2019 fiercebiotech
May 07, 2018
Celgene suffered an embarrassing setback in February when it got a refuse-to-file letter for its multiple sclerosis drug ozanimod. Now, the company says, it expects to resubmit the NDA in the first quarter of 2019, delaying its timeline by a year.